The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Cancer Immunotherapy
Opening new pathway in ex vivo cellular engineering: In article number 2304122, Yaping Chen, Nicolas H. Voelcker, Roey Elnathan, and co‐workers showcase the prowess of electroactive nanoinjection, introducing a CAR construct into primary human T cells. This endows them with enhanced attributes, notably the robust capability to inhibit lymphoma cell growth.
Chimeric antigen receptor (CAR)‐T cell therapy has emerged as a promising cell‐based immunotherapy approach for treating blood disorders and cancers, but genetically engineering CAR‐T cells is challenging due to primary T cells’ sensitivity to conventional gene delivery approaches. The current viral‐based method can typically involve significant operating costs and biosafety hurdles, while bulk electroporation...